

**IN THE SPECIFICATION:**

Please ~~amend~~ the specification as follows:

At page 4, line 15, after ~~“encoding human I5E”~~, please ~~insert~~ the phrase  
-- (SEQ ID NOS:1-2) --.

At page 4, line 17, after ~~“encoding mouse I5E”~~, please ~~insert~~ the phrase  
-- (SEQ ID NOS:3-4) --.

At page 77, line 17, after ~~“...GTCGG-3”~~, please ~~insert~~ the phrase  
-- (SEQ ID NO:5) --.

At page 77, line 18, after ~~“...TACCG-3”~~, please ~~insert~~ the phrase  
-- (SEQ ID NO:6) --.

At page 79, line 36, after ~~“...AGATG-3”~~, please ~~insert~~ the phrase  
-- (SEQ ID NO:7) --.

At page 80, line 1, after ~~“...CACTA-3”~~, please ~~insert~~ the phrase  
-- (SEQ ID NO:8) --.

**REMARKS**

Applicants have cancelled Claims 1-15, without prejudice to Applicants' rights to pursue the subject matter of the claims in related applications. Applicants have amended Claims 16, 17, 52 and 60 to more particularly point out and distinctly claim the subject matter of the invention. The amendments to the claims are fully supported by the instant specification, see, *e.g.*, page 25, line 1 to page 63, line 23, and do not constitute new matter.

The specification has been amended pursuant to 37 C.F.R. § 1.821(d) to incorporate the sequence identifiers corresponding to the Sequence Listing submitted concurrently herewith. The incorporation of the sequence identifiers introduces no new matter.